000281646 001__ 281646
000281646 005__ 20251010152028.0
000281646 0247_ $$2doi$$a10.1007/s12035-025-05051-9
000281646 0247_ $$2pmid$$apmid:40402411
000281646 0247_ $$2ISSN$$a0893-7648
000281646 0247_ $$2ISSN$$a1559-1182
000281646 037__ $$aDZNE-2025-01164
000281646 041__ $$aEnglish
000281646 082__ $$a570
000281646 1001_ $$aAyoub, Sama$$b0
000281646 245__ $$aGlycation in Alzheimer's Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions.
000281646 260__ $$aTotowa, NJ$$bHumana Press$$c2025
000281646 3367_ $$2DRIVER$$aarticle
000281646 3367_ $$2DataCite$$aOutput Types/Journal article
000281646 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1760102342_23892$$xReview Article
000281646 3367_ $$2BibTeX$$aARTICLE
000281646 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281646 3367_ $$00$$2EndNote$$aJournal Article
000281646 520__ $$aAs global life expectancy increases, the prevalence of neurodegenerative diseases like Alzheimer's disease (AD) continues to rise. Since therapeutic options are minimal, a deeper understanding of the pathophysiology is essential for improved diagnosis and treatments. AD is marked by the aggregation of Aβ proteins, tau hyperphosphorylation, and progressive neuronal loss, though its precise origins remain poorly understood. Meanwhile, type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia, leading to the formation of advanced glycation end products (AGEs), which are implicated in tissue damage and neurotoxicity. These AGEs can be resistant to proteolysis and, therefore, accumulate, exacerbating AD pathology and accelerating neurodegeneration. Insulin resistance, a hallmark of T2DM, further complicates AD pathogenesis by promoting tau hyperphosphorylation and Aβ plaque accumulation. Additionally, gut microbiome dysbiosis in T2DM fosters AGE accumulation and neuroinflammation, underscoring the intricate relationship between metabolic disorders, gut health, and neurodegenerative processes. This complex interplay presents both a challenge and a potential avenue for therapeutic intervention. Emerging evidence suggests that antidiabetic medications may offer cognitive benefits in AD, as well as in other neurodegenerative conditions, pointing to a shared pathophysiology. Thus, we posit that targeting AGEs, insulin signaling, and gut microbiota dynamics presents promising opportunities for innovative treatment approaches in AD and T2DM.
000281646 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000281646 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281646 650_7 $$2Other$$aAdvanced glycation end products (AGEs)
000281646 650_7 $$2Other$$aAlzheimer’s disease
000281646 650_7 $$2Other$$aDual drugs
000281646 650_7 $$2Other$$aType 2 diabetes
000281646 650_7 $$2NLM Chemicals$$aGlycation End Products, Advanced
000281646 650_7 $$2NLM Chemicals$$aHypoglycemic Agents
000281646 650_2 $$2MeSH$$aAlzheimer Disease: drug therapy
000281646 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000281646 650_2 $$2MeSH$$aHumans
000281646 650_2 $$2MeSH$$aDiabetes Mellitus, Type 2: drug therapy
000281646 650_2 $$2MeSH$$aDiabetes Mellitus, Type 2: metabolism
000281646 650_2 $$2MeSH$$aGlycation End Products, Advanced: metabolism
000281646 650_2 $$2MeSH$$aAnimals
000281646 650_2 $$2MeSH$$aHypoglycemic Agents: therapeutic use
000281646 650_2 $$2MeSH$$aHypoglycemic Agents: pharmacology
000281646 650_2 $$2MeSH$$aGastrointestinal Microbiome: drug effects
000281646 7001_ $$aArabi, Maryam$$b1
000281646 7001_ $$aAl-Najjar, Yousef$$b2
000281646 7001_ $$aLaswi, Ibrahim$$b3
000281646 7001_ $$0P:(DE-2719)2814138$$aOuteiro, Tiago F$$b4$$udzne
000281646 7001_ $$aChaari, Ali$$b5
000281646 773__ $$0PERI:(DE-600)2079384-4$$a10.1007/s12035-025-05051-9$$gVol. 62, no. 11, p. 14859 - 14882$$n11$$p14859 - 14882$$tMolecular neurobiology$$v62$$x0893-7648$$y2025
000281646 8564_ $$uhttps://pub.dzne.de/record/281646/files/DZNE-2025-01164.pdf$$yRestricted
000281646 8564_ $$uhttps://pub.dzne.de/record/281646/files/DZNE-2025-01164.pdf?subformat=pdfa$$xpdfa$$yRestricted
000281646 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814138$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000281646 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000281646 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-07$$wger
000281646 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-07$$wger
000281646 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000281646 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000281646 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000281646 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000281646 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000281646 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000281646 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000281646 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000281646 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL NEUROBIOL : 2022$$d2025-01-07
000281646 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL NEUROBIOL : 2022$$d2025-01-07
000281646 9201_ $$0I:(DE-2719)1410002$$kAG Fischer$$lEpigenetics and Systems Medicine in Neurodegenerative Diseases$$x0
000281646 980__ $$ajournal
000281646 980__ $$aEDITORS
000281646 980__ $$aVDBINPRINT
000281646 980__ $$aI:(DE-2719)1410002
000281646 980__ $$aUNRESTRICTED